Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Decuroside I shows weak inhibiting activity against the primary and secondary wave aggregation of human platelet.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 3,330 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 5,080 | 待询 |
产品描述 | Decuroside I shows weak inhibiting activity against the primary and secondary wave aggregation of human platelet. |
体外活性 | METHODS AND RESULTS:Three kinds of new coumarin-glycosides, Decuroside I (1), Decuroside II (2), Decuroside III (3), which were isolated from the N-butanol extracts of the crude drug Zi-Hua Qian-Hu, the root of PEUCEDANUM DECURSIVUM Maxim. (Umbelliferae), were elucidated to be nodakenetin-4′- O-β-gentiobiose, nodakenetin-4′- Oβ-isomaltose and nodakenetin-4′- O-β-maltose, respectively, by the methods of chemical and spectral analysis. These three new compounds as well as Decuroside IV (4), decuroside V (5) and nodakenin (6) which were also isolated from Zi-Hua Qian-Hu were tested on human platelet aggregation induced by 2 μM ADP. CONCLUSIONS:Among these coumarin-glycosides, 3 and 4, showed the strongest inhibiting activity against the primary and secondary wave aggregation of human platelet. 1 and 2 had a less inhibiting effect or none at all, and 5 was rather promotive against the primary wave aggregation. |
分子量 | 570.544 |
分子式 | C26H34O14 |
CAS No. | 96638-79-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Decuroside I 96638-79-8 Inhibitor inhibitor inhibit